Hafnia Limited Common Shares vs Vaxcyte Inc. Common Stock — how do they compare? Hafnia Limited Common Shares trades at $10.59 (market cap $5.76B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| HAFN | PCVX | |
|---|---|---|
Market Cap | $5.76B | $10.51B |
Volume | 1,835,725 | 2,644,694 |
Sector | Industrials | Health |
52-Week High | $10.92 | $73.82 |
52-Week Low | $5.21 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.37B | $9.14B |
Dividend Yield | 10.24% | — |
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →